TIMP3 and achalasia-alacrima syndrome: Taken together, these findings imply a dual beneficial effect of miR-181b inhibition during atherosclerosis and AAAs, namely increased macrophage TIMP-3 protein expression and heightened VSMC elastin production, which could eventually be exploited therapeutically.